Alkermes plc
Alkermes plc (ALKS) Covered Calls
Alkermes plc trades in the Drug Manufacturers - Specialty & Generic industry with an IV Rank of 23.02%, low versus the past year. ALKS's highest covered call setup is the $55.00 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 22.52% out of the money with 74 days to expiration, a 23.86% return until expiration, and a 117.68% theoretical annualized return. Across the setups shown, annualized returns run from 49.23% to 117.68% at strikes between $46.00 and $75.00, with 18 to 445 days to expiration, as of Nov 2, 2026.
Read more
Running ALKS covered calls helps you generate income from Alkermes plc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ALKS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ALKS stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ALKS covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ALKS covered call is worth writing.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.
| 2027-01-15 | 74 | 55.00 | 22.52 | 0.60 | 1.65 | 1071.00 | 23.86 | 117.68 | -1.34 | +0.22 | 40 | 1.05 |
| 2026-11-20 | 18 | 47.00 | 4.70 | 0.20 | 2.80 | 231.00 | 5.15 | 104.35 | -0.45 | +0.39 | 94 | 2.60 |
| 2026-12-18 | 46 | 49.00 | 9.16 | 0.65 | 3.50 | 476.00 | 10.60 | 84.14 | -1.45 | +0.38 | 3 | 2.85 |
| 2026-12-18 | 46 | 48.00 | 6.93 | 1.00 | 3.80 | 411.00 | 9.16 | 72.65 | -2.23 | +0.42 | 2 | 2.80 |
| 2027-01-15 | 74 | 50.00 | 11.38 | 1.25 | 3.10 | 636.00 | 14.17 | 69.88 | -2.78 | +0.36 | 74 | 1.85 |
| 2027-05-21 | 200 | 60.00 | 33.66 | 0.30 | 4.30 | 1541.00 | 34.33 | 62.65 | -0.67 | +0.28 | 0 | 4.00 |
| 2026-12-18 | 46 | 47.00 | 4.70 | 1.35 | 4.30 | 346.00 | 7.71 | 61.16 | -3.01 | +0.46 | 4 | 2.95 |
| 2028-01-21 | 445 | 75.00 | 67.08 | 1.15 | 5.50 | 3126.00 | 69.64 | 57.12 | -2.56 | +0.28 | 2 | 4.35 |
| 2026-11-20 | 18 | 46.00 | 2.47 | 0.15 | 3.80 | 126.00 | 2.81 | 56.92 | -0.33 | +0.46 | 52 | 3.65 |
| 2027-05-21 | 200 | 55.00 | 22.52 | 2.00 | 4.40 | 1211.00 | 26.98 | 49.23 | -4.46 | +0.36 | 2 | 2.40 |
As of Nov 2, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →Stock Statistics
- IndustryDrug Manufacturers - Specialty & Generic
- SectorHealthcare
- IV Rank23.02% Low
- Market cap (M$)7,665
- 52 weeks high-17.93%
- 52 weeks low69.22%
- Analyst recommendationBuy
1.63 - Target price$56.47
23.59% above the current stock price - Dividend—
- Payout ratio0.00%
- Earnings date2026-11-03
- P/E118.68
- Future P/E79.81
- EPS (ttm)0.39
- EPS growth next 5 years-10.94%
As of Nov 2, 2026